Clinical trialNCT04281498CompletedPhase 2Interventional

Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation

SponsorJohn MascarenhasEnrollment6Accelerated/Blast-phase Myeloproliferative NeoplasmChronic-phase MyelofibrosisIDH2 Mutation

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The presence of IDH mutation is associated with worse survival in patients with myelofibrosis. Moreover IDH mutations are among the most frequently encountered events in MPNs that have progressed to acute myeloid leukemia. Ruxolitinib, a JAK1/2 inhibitor, and enasidenib an IDH2 inhibitor are effective and tolerable treatments for patients with myelofibrosis (MF) and acute myeloid leukemia (AML), respectively. The study team hypothesize that the combination of these agents in patients with MPN with an IDH2 mutation will improve the overall clinical response to therapy.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

John Mascarenhas, MD
Icahn School of Medicine at Mount Sinai
Study Chair
clinicaltrials.gov ↗
Michal Bar-Natan, MD
Icahn School of Medicine at Mount Sinai
Principal Investigator
clinicaltrials.gov ↗
Ronald Hoffman, MD
Icahn School of Medicine at Mount Sinai
Study Chair
clinicaltrials.gov ↗
Ruben Mesa, MD
Mays Cancer Center at UT Health
Study ChairKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

11 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Canada

Princess Margaret Cancer Centre
Toronto, Canada

United States

Mayo Clinic - Arizona
Scottsdale, Arizona, United States
Cedars-Sinai Medical Center
Los Angeles, California, United States
Moffitt Cancer Center
Tampa, Florida, United States
University of Kansas Cancer Center
Westwood, Kansas, United States
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan, United States
Icahn School of Medicine at Mount Sinai
New York, New York, United States
Memorial Sloan-Kettering Cancer Center
New York, New York, United States
Wake Forest Baptist Health
Winston-Salem, North Carolina, United States
Taussig Cancer Center Institute
Cleveland, Ohio, United States
Mays Cancer Center at Ut Health San Antonio
San Antonio, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Enasidenib →Ruxolitinib →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 14 Jan 2021
Primary completion: 30 May 2023
Completion: 30 May 2023
Last update posted: 4 Feb 2025
Registered enrollment: 6
Registry id: NCT04281498

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.